Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc. files under the ticker DECA following its business combination with Decathlon Acquisition Corp., a blank-check company that targeted the life sciences and biopharmaceutical sector. Decathlon Acquisition Corp. completed its initial public offering in 2021 and subsequently closed its de-SPAC transaction with Semnur, which is focused on developing treatments for spine-related pain conditions. The combined company submitted a Form 10-Q to the Securities and Exchange Commission on May 22, 2024, reflecting its status as a post-merger operating public entity. For complete filing history, financials, and SPAC analytics on DECA, visit SpacDesk and sign up for full data access.